5-Arylbenzothiadiazine Type Compounds as Positive Allosteric Modulators of AMPA/Kainate Receptors
摘要:
The potential therapeutic benefit of compounds able to activate AMPA receptors (AMPAr) has led to the search for new AMPAr positive modulators. On the basis of crystallographic data of the benzothiadiazines binding mode in the S1S2 GluA2 dimer interface, a set of 5-aryl-2,3-dihydrobenzothiadiazine type compounds has been synthesized and tested. Electrophysiological results suggested that 5-heteroaryl substituents on the benzothiadiazine core like 3-furanyl and 3-thiophenyl dramatically enhance the activity as positive modulators of AMPAr with respect to IDRA21 and cyclothiazide. Mouse brain microdialysis studies have suggested that 7-chloro-5-(3-furyl)-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide crosses the blood-brain barrier after intraperitoneal injection. Biological results have been rationalized by a computational docking simulation that it has currently employed to design new AMPAr-positive modulator candidates.
Novel compounds and their use as positive AMPA receptor modulators
申请人:Neurosearch A/S.
公开号:US20040043987A1
公开(公告)日:2004-03-04
The invention provides novel compounds represented by the general formula 5 compound represented by the formula:
1
wherein
the bond represented by the broken line may be a single, a double bond or absent;
and if the bond is absent, then the nitrogen is substituted with a hydrogen and R
2
;
X represents SO
2
or C═O or CH
2
;
Y represents —CH(R
4
)—, —N(R
4
)— or —N(R
4
)—CH
2
—, O;
and the meaning of R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, and R
8
are as defined in the application
The compounds are useful as positive modulators of the AMPA-receptor.
Derivatives of 1,2,4-benzothiadiazine dioxide, their preparation and use as allosteric modulators of the AMPA receptor
申请人:Universita'del Salento
公开号:EP2457906A1
公开(公告)日:2012-05-30
A compound of formula I is described:
which showed to be surprisingly and significantly effective as an allosteric modulator of the AMPA receptor and is therefore particularly suitable for the treatment of mnemocognitive disorders ascribable to an alteration of glutamatergic neurotransmission, such as age-related disorders, anxiety, progressive neurodegenerative disorders, depressive disorders, schizophrenia, obsessive-compulsive disorders and bipolar disorder.